GSK Precision Medicine, Biomarker & Bioanalytical Platforms, 1250 S Collegeville Rd, Collegeville, PA 19426, USA.
GSK Research Statistics, Biostatistics, 1250 S Collegeville Rd, Collegeville, PA 19426, USA.
Bioanalysis. 2024;16(14):735-745. doi: 10.1080/17576180.2024.2360363. Epub 2024 Jun 17.
To redevelop a neutralizing antibody (NAb) assay to be much more drug tolerant, have a large dynamic range and have high inhibition when using high levels of positive control (PC). Early assay data suggested that typical biotin labeling of the capture reagent (Drug 1, produced in a human cell line) was blocking it from binding with the PC or the detection target, and that the detection target was out competing the PC. Methodical biotin labeling experiments were performed at several challenge ratios and an Fc linker was added to the detection target. A larger dynamic range, high inhibition and higher drug tolerance were achieved by adding an acid dissociation step to the assay, performing atypical biotin labeling of Drug 1 and switching to a detection target that contained an Fc linker to increase steric hinderance and decrease its binding affinity to Drug 1.
为了开发一种对药物更耐受、动态范围更大、在使用高水平阳性对照(PC)时具有高抑制性的中和抗体(NAb)检测方法。早期的检测数据表明,捕获试剂(Drug 1,在人细胞系中产生)的典型生物素标记会阻止其与 PC 或检测靶标结合,并且检测靶标会与 PC 竞争。在几个挑战比下进行了系统的生物素标记实验,并在检测靶标中添加了 Fc 接头。通过在检测方法中添加酸解离步骤、对 Drug 1 进行非典型生物素标记,并切换到含有 Fc 接头的检测靶标以增加空间位阻并降低其与 Drug 1 的结合亲和力,实现了更大的动态范围、高抑制性和更高的药物耐受性。